Kalaris to Present Early TH103 Clinical Data July 17; Phase 1b/2 Trial Actively Enrolling
Summary
Kalaris Therapeutics announced it will present Phase 1a clinical data for its TH103 drug candidate on July 17, 2026, at the American Society of Retina Specialists meeting. The company also confirmed active enrollment and dosing in its Phase 1b/2 trial for TH103. This operational progress is important for the clinical-stage biotech, especially following recent financial disclosures of increased losses and a shortened cash runway into Q2 2027. The upcoming data presentation provides a near-term catalyst for the stock. Initial data from the Phase 1b/2 study is expected in 1H 2027.
At the time of this announcement, KLRS was trading at $4.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96M. The 52-week trading range was $2.14 to $11.88. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.